Form 4: CFO Callicutt Exercises, Sells GALT Stock Under 10b5-1 Plan

Galectin Therapeutics CFO Jack W. Callicutt exercised stock options and subsequently sold an equal number of shares totaling 5,291 under a pre-arranged 10b5-1 plan.

Summary

• Jack W. Callicutt, Chief Financial Officer of Galectin Therapeutics Inc. (GALT), reported transactions on November 10, 2025, executed under a Rule 10b5-1 plan adopted on April 17, 2025.
• Callicutt exercised stock options to acquire a total of 5,291 shares of common stock: 1,880 shares at $1.98, 1,675 shares at $1.11, and 1,736 shares at $1.23.
• Concurrently, he sold the same 5,291 shares of common stock: 1,880 shares at a weighted average price of $6.022, 1,675 shares at $6.0266, and 1,736 shares at $6.0298.
• Following these transactions, Callicutt's direct beneficial ownership of common stock remained at 7,614 shares.
• He also directly owns 126,670 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing reports routine, pre-arranged insider transactions (exercise of options and immediate sale of the same number of shares) under a 10b5-1 plan. While the executive realized a profit, there is no net change in direct common stock ownership, and the transaction does not convey new information about the company's operational performance or future outlook.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 plan, indicating planned activity rather than reactive trading, which reduces concerns about discretionary insider selling.
• The sale prices ($6.022, $6.0266, $6.0298) are significantly higher than the exercise prices ($1.98, $1.11, $1.23), indicating a profitable exercise and sale for the CFO.

Future Outlook

NA

Management Comments

• The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.
• The shares were sold in multiple transactions at prices ranging from $6.00 to $6.14. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Industry Context

This Form 4 filing details routine insider transactions (option exercises and sales) by a company executive. Such transactions are common and generally do not reflect broader industry trends unless they are unusually large or frequent across multiple executives, which is not indicated here.

Stakeholder Impact

• Shareholders: The planned exercise and sale of shares by the CFO, while profitable for the executive, does not signal new material information about the company's prospects. The net effect on direct common stock ownership is neutral.
• Employees: No direct impact mentioned.

Next Steps

• Continued vesting of 1,736 stock options on December 31, 2025, June 30, 2026, and December 31, 2026.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions (exercise of options and subsequent sale of the same number of shares) by the CFO under a pre-arranged 10b5-1 plan. The transactions resulted in no net change to the CFO's direct common stock holdings. This type of planned activity is common and does not signal new material information about the company's performance or future prospects. Therefore, it does not warrant a change in investment thesis based solely on this filing. A 'hold' recommendation is appropriate as this is a standard, non-eventful insider transaction.

Keywords

Galectin Therapeutics, GALT, Form 4, Insider Trading, Stock Options, CFO, Jack W. Callicutt, Rule 10b5-1 Plan, Equity Sales